Kannaway, the direct selling subsidiary of Medical Marijuana, Inc., recently participated in an industry-led cannabidiol (CBD) Safety Study, for which Validcare acted as CRO. The study, completed March 22, 2022, released preliminary results that demonstrate an overwhelmingly positive safety profile for CBD.
Kannaway participated in this study along with 16 other CBD companies who provided certificates of analysis (COAs) confirming third-party label accuracy, and 1,061 U.S. participants. The study specifically highlighted the impact of daily consumption of CBD across a range of retail products and serving sizes, illustrating so far that CBD is not associated with elevated liver tests, low testosterone levels or daytime drowsiness.
“We hope that these results, paired with the results from the first cohort of the study, will persuade the FDA to take steps to regulate CBD,” said Blake Schroeder, Medical Marijuana, Inc. and Kannaway Chief Executive Officer. “If this were to happen, we could expect the addressable market size to double from present levels as more large chain retailers become more comfortable with the sales of these CBD products upon their shelves and fewer consumers feel hesitant about trying CBD.”
